1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Chengdu Olymvax Biopharmaceuticals Inc. Class A

Chengdu Olymvax Biopharmaceuticals Inc. Class A

SSSE:688319
26.88
CNY
+0.68
(+2.60%)
-0.09EPS
17.83BMarket Cap
Oct 30Next Earn
Chengdu Olymvax Biopharmaceuticals Inc. Class A
SSE:688319
(Shanghai Stock Exchange)

Recent

price

26.88

P/E

ratio

- -

div

yld

0.15%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
- -
- -
- -
- -
0.07
0.37
0.5
0.88
1.27
1.35
1.22
1.45
1.74
1.92
Revenue per Share
-0.11
-0.22
-0.31
-0.29
-0.13
-0.09
-0.09
0.1
0.28
0.07
0.04
0.05
0.05
-0.09
Basic EPS, GAAP
-0.29
-0.18
-0.24
-0.26
-0.18
-0.17
-0.2
-0.05
-0.08
-0.56
-0.31
-0.54
0.02
- -
Free Cash Flow per Basic Share
0.02
0.03
0.02
0.01
- -
- -
- -
- -
- -
0.01
0.01
0.07
0.04
0.04
Dividend per Share
0.82
0.72
1.01
0.88
1.04
0.95
0.93
1.03
2.08
2.18
2.26
2.28
2.23
2.14
Book Value per Share
0.75
0.65
0.94
0.81
0.98
0.88
0.86
0.95
1.99
1.83
1.76
1.54
1.33
1.23
Tangible Book Value per Share
206
137
169
191
203
206
361
365
385
405
405
405
405
405
Basic Weighted Avg Shares
- -
- -
- -
- -
15
76
179
320
487
547
496
589
704
777
Sales/Revenue/Turnover
-4,154.45
-15,975.7
-12,682.91
-34,637.99
-195.32
-25.09
100
12.91
21.68
10.16
2.66
6.44
10.15
14.8
Operating Margin (%)
5
7
16
9
10
9
7
18
23
25
31
32
39
- -
Depreciation Expense
-23
-30
-52
-56
-27
-19
-31
36
108
27
18
21
22
-38
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.11
26.74
29.52
31.34
251.36
Effective Tax Rate (%)
-4,664.27
-17,770.36
-12,485.6
-34,430.73
-186.67
-24.9
-17.33
11.29
22.16
4.85
3.54
3.53
3.16
-4.87
Profit Margin (%)
29
-14
9
-9
21
-8
112
123
533
411
455
313
259
239
Working Capital
42
42
- -
- -
- -
- -
- -
2
3
39
182
250
331
322
LT Debt
168
147
207
180
213
194
341
377
845
892
931
934
904
869
Total Equity
- -
- -
- -
- -
- -
- -
- -
9.01
- -
2.7
0.21
1.25
1.66
-6.01
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
9.78
- -
3.06
2.64
2.91
2.48
-4.61
Return on Capital (%)
- -
-19.19
-29.58
-28.68
-13.83
-9.32
-11.6
10.07
17.68
3.08
1.95
2.25
2.43
-4.23
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
102
135
202
LT Borrowings
324
296
318
LT Finance Leases
7
4
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
406
406
405
Market Capitalization
10,294
11,796
17,830

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
996
999
1,075
Cash, Cash Equivalents & STI
249
195
235
Accounts Receivable, Net
656
707
746
Inventories
62
66
61
Total Current Liabilities
737
737
836
Payables & Accruals
- -
- -
- -
ST Debt
102
135
202
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.37%
26.23%
-3.16%
Free Cash Flow
67.16%
129.99%
-103.08%
Net Income, GAAP
-11.32%
23%
7.24%
Sales/Revenue/Turnover
961.62%
18.69%
19.58%
Total Cash Common Dividend
97.16%
147.12%
-50.41%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
71
155
160
202
589
2025
87
218
- -
197
704
2026
158
204
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
- -
0.08
0.04
0.05
2025
-0.02
0.05
- -
-0.06
0.05
2026
0.07
-0.15
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.05
0.01
0.01
0.07
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) is a biotechnology company focused on the research, development, manufacturing, and commercialization of vaccines and biopharmaceutical products. The company offers a portfolio of vaccines including the AC-Hib combined vaccine for diphtheria, tetanus, whole-cell pertussis, and Haemophilus influenzae type b; the ACYW meningococcal conjugate vaccine; the EV71 hand-foot-mouth disease vaccine; the oral rotavirus vaccine; and the 13-valent pneumococcal conjugate vaccine (PCV13), among others such as influenza and COVID-19 vaccines. It provides contract development and manufacturing organization (CDMO) services for biopharmaceuticals, encompassing process development, clinical trial materials production, and commercial-scale manufacturing. Olymvax operates primarily in China with expanding international presence in Asia and beyond, targeting pediatric, adolescent, and adult populations through public health programs and private markets. Founded in 2001 and headquartered in Chengdu, Sichuan Province, China, the company serves the biopharmaceutical industry with segments in human vaccines, animal health products, and biomanufacturing services. Its target customers include government procurement for national immunization programs, hospitals, and pharmaceutical distributors. Olymvax maintains subsidiaries focused on research and international sales, with no publicly disclosed parent company. In recent developments within the last two years, Olymvax expanded its production capacity through a new Phase III facility for PCV13 vaccine, achieving commercial launch approvals from China's National Medical Products Administration in 2024. The company formed strategic partnerships with global biopharma firms for technology transfer in mRNA vaccine platforms and secured funding for R&D in next-generation pneumococcal vaccines. Additionally, it announced expansions into Southeast Asian markets via distribution alliances and initiated clinical trials for a hexavalent DTaP-based combination vaccine in 2025.